BioCentury
ARTICLE | Clinical News

AEG35156: Phase II started

February 1, 2010 8:00 AM UTC

Aegera began an open-label, Hong Kong Phase II trial to evaluate Nexavar sorafenib with or without AEG35156 in 50 patients. Bayer AG (Xetra:BAY, Leverkusen, Germany) and Onyx Pharmaceuticals Inc. (...